Table 4.
Comparison of patient clinical data with TMTV and TLG
| Variable | No. of patients (n = 84) | TMTV | TLG | ||||
|---|---|---|---|---|---|---|---|
| Low (n = 43) | High (n = 41) | P value* | Low (n = 35) | High (n = 49) | P value* | ||
| Sex, F/M | 30/54 | 15/28 | 15/26 | 1.000 | 14/21 | 16/33 | 0.499 |
| Age, ≤ 60/> 60 | 43/41 | 25/18 | 18/23 | 0.275 | 21/14 | 22/27 | 0.191 |
| LDH level, normal/elevated | 38/46 | 24/19 | 14/27 | 0.052 | 21/14 | 17/32 | 0.027 |
| B symptoms, no/yes | 33/51 | 23/20 | 10/31 | 0.008 | 18/17 | 15/34 | 0.071 |
| ECOG PS, 0–1/ ≥ 2 | 57/27 | 35/8 | 22/19 | 0.010 | 28/7 | 29/20 | 0.059 |
| Ann Arbor stage, I–II/III–IV | 15/69 | 11/32 | 4/37 | 0.087 | 10/25 | 5/44 | 0.043 |
| Extranodal sites ≥ 2, no/yes | 65/19 | 36/7 | 29/12 | 0.196 | 29/6 | 36/13 | 0.429 |
| BMB, negative/positive | 63/21 | 36/7 | 27/14 | 0.079 | 28/7 | 35/14 | 0.449 |
| Ki-67 ≥ 80%, no/yes | 60/24 | 33/10 | 27/14 | 0.336 | 26/9 | 34/15 | 0.807 |
| Platelet cell count, ≥ 150 × 109/L | 48/36 | 24/19 | 24/17 | 0.829 | 22/13 | 26/23 | 0.503 |
| IPI, 0–2/3–5 | 47/37 | 34/9 | 13/28 | < 0.001 | 27/8 | 20/29 | 0.002 |
| PIT, 0–1/2–4 | 41/43 | 29/14 | 12/29 | 0.001 | 24/11 | 17/32 | 0.004 |
| IPTCLP, 0–1/2, 3 | 54/30 | 31/12 | 23/18 | 0.172 | 26/9 | 28/21 | 0.165 |
A chi-square test was used to test the significance of the association between clinical data and the baseline TMTV and TLG
LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy, IPI International Prognostic Index, PIT prognostic index for T-cell lymphoma, IPTCLP International peripheral T cell lymphoma Project, MTV metabolic tumor volume, TLG total lesion glycolysis
*P < 0.05